Legacy Adagio
Total Consideration
$53.5M
Purchase-Price Allocation
Goodwill
$44.3M
Intangibles
$26.2M
Liabilities Assumed
$23.7M
Deferred Tax Liability
$2.8M
ADAGIO MEDICAL HOLDINGS, INC. — Key Metrics
1 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Working Capital Analysis
Valuation Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-2
Book Value Per Share
$1
Free Cash Flow Per Share
$-1
Cash Per Share
$1
Revenue Per Share
$0
OCF Per Share
$-1
Return on Equity
41.9%
Return on Assets
-100.2%
Return on Invested Capital
57.3%
Debt to Equity
1.70
Current Ratio
2.44
Quick Ratio
2.24
Asset Turnover
0.00
Days Sales Outstanding
—
Days Payables Outstanding
577.38
Days Inventory On Hand
892.22
Cash Conversion Cycle
—
R&D / Revenue
—
SBC / Revenue
—
Capex / Revenue
—
Working Capital
$12M
Net Current Asset Value
$-11M
Invested Capital
$33M
OCF / Net Income
0.76
FCF / Net Income
0.77
Accruals Ratio (Sloan)
-14.0%
Net Debt
$4M
Net Debt / EBITDA
-0.19
Interest Coverage
-7.53
Cash Coverage
-6.54
Capex Coverage
-50.84
Tangible Common Equity
$-9M
TCE / Total Assets
-19.7%
Goodwill / Total Assets
32.3%
NOPAT
$-17M
Cash ROIC
64.3%
WC / Revenue
—
Capex / D&A
0.39
Reinvestment Rate
2.7%
Asset Growth vs Revenue Growth
633.7%
Stock Price (FY-end)
$1
Market Cap
$17M
P/B Ratio
1.39
Enterprise Value
$21M
FCF Yield
-112.5%
Shareholder Yield
-8.6%
R&D Yield
61.7%
Capex Yield
2.2%
Beta (5Y)
0.29
Cost of Equity
6.0%
Cost of Debt (after tax)
10.9%
WACC
8.7%
ROIC - WACC Spread
48.7%
52W High
$2
52W Low
$1
Trailing Return 1Y
-1.0%
F-Score (Piotroski)
4.00
Z-Score (Altman)
-4.10
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Stock Price on Earnings Dates
ADAGIO MEDICAL HOLDINGS, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
| Reconciliation Line | FY2023 | FY2025 |
|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% |
| State & Local Income Taxes | — | — |
| Foreign Rate Differential | 0.00% | — |
| Other Adjustments | — | — |
| Nondeductible Expenses | -1.20% | — |
| Valuation Allowance Change | -7.80% | -17.20% |
| Effective Tax Rate | — | — |
Cash vs Accrual
| Item | FY2023 | FY2025 |
|---|---|---|
| Income Tax Expense (Accrual) | — | — |
| Income Taxes Paid (Cash) | — | — |
ADAGIO MEDICAL HOLDINGS, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.